Prostatectomy News and Research

RSS

Five-treatment radiation provides excellent long-term prostate cancer control

Five-treatment stereotactic body radiation therapy (SBRT) provided excellent long-term cancer control with fewer urinary and sexual side effects than surgery in the first randomized trial to directly compare the treatments for localized prostate cancer.

28 Sep 2026

Prostate cancer biology helps identify hormone therapy candidates

A recent analysis of the NRG-RTOG 0534 "SPPORT" clinical trial evaluated the Luminal B (LumB) molecular subtype using the PAM50 genomic classifier to determine whether tumor biology could help identify patients most likely to benefit from hormone therapy.

27 Sep 2026

$Hypofractionated radiotherapy for prostate cancer matches conventional treatment outcomes$

Hypofractionated radiotherapy for prostate cancer matches conventional treatment outcomes

Men with high-risk prostate cancer have a higher likelihood of having residual disease following prostatectomy and may require radiation therapy after surgery, particularly when PSA levels begin to rise. Conventional postprostatectomy radiotherapy (COPORT) is typically delivered over 37 fractions, while hypofractionated postprostatectomy radiotherapy (HYPORT) delivers a slightly lower total radiation dose over just 25 fractions.

27 Sep 2026

High-risk prostate cancer patients benefit from perioperative apalutamide therapy

High-risk localized and locally advanced prostate cancer patients treated with apalutamide - a next generation neoadjuvant androgen-receptor pathway inhibitor (ARPI) - plus hormone therapy before and after prostate cancer surgery resulted in more major pathologic responses and reduced the risk of metastasis or death, meeting both primary endpoints, in an international phase 3 clinical trial led by principal investigator Mary-Ellen Taplin, MD, medical oncologist at Dana-Farber Cancer Institute, and Adam Kibel, MD, chair of the Department of Urology at Mass General Brigham.

31 May 2026

Prostate cancer patients recover faster with TULSA than robotic surgery

A new randomized clinical trial found that men with localized, intermediate‑risk prostate cancer recovered faster and experienced less short‑term impact on their daily lives when treated with MRI‑guided, transurethral ultrasound ablation (TULSA) compared with robotic prostate surgery.

13 Apr 2026

Human insight and AI advance prostate cancer treatment

Today, many men must choose between life-altering prostate removal or careful long-term monitoring. The EU-funded ROBIOSPY Project offers an intermediate option: precise needle-based diagnostics and targeted therapy powered by AI-driven robotics.

12 Feb 2026

PSMA PET/CT scans may predict prostate cancer recurrence, guide treatment

New research in the February 2026 issue of JNCCN-Journal of the National Comprehensive Cancer Network found that incorporating information from prostate-specific membrane antigen (PSMA) PET/CT scans may be able to predict progression-free survival (PFS) and guide treatment planning in patients with rising prostate-specific antigen (PSA) levels following removal of the prostate.

9 Feb 2026

Novel laser focal therapy device shows promising results for prostate cancer treatment

Because treatment of the whole prostate can lead to long-term side effects in patients with prostate cancer, interest in minimally invasive, focal treatment options has been growing for certain patients.

28 Jan 2026

Pre-surgical medication use grows for pancreatic, gynecologic, and abdominal lining cancers

The second annual report from the National Cancer Database (NCDB) of the American College of Surgeons (ACS) documents a substantial rise in medication treatments, such as chemotherapy, immunotherapy, and hormone therapy, used before surgery to treat many cancers, often allowing less invasive surgery and helping clinicians assess how a patient's cancer responds to medication to guide the most effective treatment options.

22 Jan 2026

Understanding sevoflurane-induced neurogenesis inhibition and cognitive dysfunction in children

Every year, millions of infants and children undergo surgery under general anesthesia in the world. Sevoflurane is a commonly used pediatric anesthetic. Its exposure during brain development has been shown to inhibit neurogenesis and cause cognitive dysfunction in animal models.

5 Jan 2026

Single-port robotic surgery transforms cancer care at NYU Langone Hospital—Long Island

After enduring seven prior abdominal surgeries, 64-year-old Joy Monetti from Islip was no stranger to painful procedures and lengthy recoveries.

17 Nov 2025

Gene expression test identifies prostate cancer patients who benefit from hormone therapy

A new randomized study finds that a lab test that reads tumor genes can identify which patients with recurrent prostate cancer will benefit from adding hormone therapy to radiation after surgery - the first predictive biomarker in this setting.

29 Sep 2025

UCLA presents advances in radiation therapy at ASTRO 2025

Physicians and scientists from the UCLA Health Jonsson Comprehensive Cancer Center will share the latest research and clinical trial results at the 2025 American Society for Radiation Oncology (ASTRO) Annual Meeting, including studies on targeted radioactive therapy for recurrent prostate cancer, new approaches to stereotactic body radiation for prostate and head and neck cancers, advances in MRI- and 5DCT-guided imaging for more precise treatments, and innovations in patient-focused cancer education.

26 Sep 2025

Frailty and microbial imbalance drive GI complications in bladder cancer surgery

Gastrointestinal (GI) complications, such as postoperative ileus (POI) and intra-abdominal infections (IAI), remain a major concern after radical cystectomy for bladder cancer.

8 Sep 2025

Androgen deprivation therapy lowers satisfaction after penile prosthesis surgery

Prostate cancer is the most common malignancy among men, with over 160,000 new cases diagnosed annually in the United States.

1 Sep 2025

New 'dual-mode' tracer agent enhances precision in prostate cancer procedures

A preclinical evaluation of a new 'dual-mode' tracer agent shows promise in not only helping surgeons image and plan prostate cancer procedures, but also provide them with much more consistent and targeted guidance during surgery.

21 Aug 2025

PSMA PET/CT improves outcomes for men with recurrent prostate cancer

A new study from Denmark shows for the first time that men with biochemically recurrent prostate cancer who undergo PSMA PET/CT before salvage radiotherapy have improved survival rates compared to those who do not.

14 Aug 2025

Rethinking prostate cancer risk in GG1 diagnoses

A new study reveals that some men who are diagnosed with "Grade Group one" (GG1) prostate cancer may actually be at higher risk than biopsy results suggest, according to research led by Weill Cornell Medicine, University Hospitals Cleveland and Case Western University.

31 Jul 2025

Shorter radiation treatment after surgery found safe for prostate cancer patients

For men who undergo a radical prostatectomy for the treatment of prostate cancer, post-surgery radiation therapy can play a vital role in reducing the risk of recurrence.

15 May 2025

Prostate cancer diagnosis is not a death sentence, study says

Prostate cancer statistics can look scary: 34,250 U.S. deaths in 2024. 1.4 million new cases worldwide in 2022.

24 Apr 2025